EXAGEN INC.
About EXAGEN INC.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $66.6M
- Net income
- -$20.0M
- Total assets
- $58.0M
- Market cap
- $103.6M
- Gross margin
- 58.3%
- Operating margin
- -21.1%
- Net margin
- -30.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $66.6M
- Cost of revenue
- $27.8M
- Gross profit
- $38.8M
- Operating expenses
- $52.9M
- Operating income
- -$14.1M
- Income tax
- $51.0K
- Net income
- -$20.0M
- EPS (basic)
- $-0.93
- EPS (diluted)
- $-0.93
Balance sheet
- Total assets
- $58.0M
- Current assets
- $48.9M
- Total liabilities
- $40.6M
- Current liabilities
- $14.2M
- Shareholders’ equity
- $17.4M
Cash flow
- Operating cash flow
- -$13.6M
- Investing cash flow
- -$626.0K
- Financing cash flow
- $24.4M
- Net cash flow
- $10.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $103.6M
- EPS (diluted)
- $-0.93
- Shares outstanding
- 24.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 19, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $20.0M in FY2025.
- Revenue grew 38% from FY2021 to FY2025.
- Gross margin of 58.3%, net margin -30.0%.
- Trading 65% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review EXAGEN INC..
Write a review
News about EXAGEN INC.
News & sentiment via Polygon.io
